

The New Frontier of IO Drug Development: Bispecifics, *in vivo* CAR T, and Novel Combinations

A SITC 2025 Pre-Conference Program
Wednesday, Nov. 5, 2025 | 2–5:10 p.m. ET



LEARN MORE & REGISTER AT [SITCANCER.ORG/2025](https://sitcancer.org/2025)

About the Industry Program

This half-day program will bring together leaders in the pharmaceutical industry along with leaders in other facets of the immuno-oncology (IO) drug development community to discuss ongoing research and the advancement of novel platforms.



Access the latest research in IO from across the globe including sessions on:

- Bispecifics
- In vivo CAR Ts
- Next Wave IO Drug Development



The program will feature leaders in academia, biotechnology, and industry addressing the latest strategies and promising clinical signs in the development of novel immuno-oncology platforms.

Consider Joining Today



Members receive a discount on registration rates and early access to housing for SITC 2025, our 40th Anniversary Annual Meeting and Pre-Conference Programs. Not a member? Join today at sitcancer.org/join.

Organizers



Jane Anne Healy, MD, PhD
Merck & Co.



Priti Hegde, PhD
Kite Pharma, Inc.



Holger Kissel, PhD
BioNTech SF



Alexandra Snyder, MD
Generate Biomedicines



Zhen Su, MD, MBA
Marengo Therapeutics